Skip to main content
OpenTrials
Completed

NCT Number: NCT07343973

Post-Market Study on the Safety and Effectiveness of the OpHLINE OVD in Cataract Surgery

This post-market clinical study was designed to assess the safety and effectiveness of the OpHLINE Ophthalmic Viscosurgical Device (OVD) as an adjunct in cataract surgery. OpHLINE is a sterile, viscoelastic solution based on high-molecular-weight sodium hyaluronate, intended to maintain the anterior chamber space and protect corneal endothelial cells during phacoemulsification and intraocular lens (IOL) implantation.

The hypothesis is that OpHLINE, available in three concentrations (1.4%, 2%, and 3%), will provide optimal space maintenance throughout all surgical phases-capsulorhexis, hydrodissection, phacoemulsification, and IOL insertion-while ensuring ease of removal and minimizing postoperative complications. Specifically, the study expects the device to demonstrate high biocompatibility, effective protection of corneal endothelial cells, and a low incidence of adverse events, including intraocular pressure (IOP) spikes.

The objectives include confirming compliance with current clinical performance standards and collecting surgeons' feedback on handling and usability. This evaluation aims to strengthen real-world evidence supporting OpHLINE as a safe and reliable solution for cataract surgery, ensuring patient safety and surgical efficiency.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Cataract Surgery

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Basurto University Hospital, Bilbao, Bizkaia, Spain

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Adults aged 18 years or older scheduled for cataract extraction by phacoemulsification, followed by implantation of a posterior chamber intraocular lens (IOL) in a single eye (operative eye).
  • The non-operative eye must be functional, as assessed by the investigator.

Exclusion criteria

  • Ocular hypertension (IOP ≥ 22 mmHg).
  • Corneal endothelial damage (cell count < 2000 cells/mm²).
  • History of chronic or recurrent ocular inflammatory disease.
  • Chronic or recurrent uveitis.
  • Acute ocular disease.
  • Internal or external ocular infection.
  • Glaucoma or proliferative diabetic retinopathy.
  • Previous ocular trauma before surgery.
  • Congenital ocular anomalies or iris atrophy.
  • Any other ocular pathology or physiological condition that could be worsened by cataract surgery.
  • Previous ocular surgery.

Treatment and study plan

Cataract Surgery by Phacoemulsification with Posterior Chamber Intraocular Lens Implantation (OpHLINE 1.4%)

Device

Eligible patients underwent cataract removal by phacoemulsification, followed by implantation of a posterior chamber intraocular lens (IOL) in a single eye.

The surgical procedure included the following steps:

Capsulorhexis: creation of a continuous circular opening in the anterior capsule of the lens.

Hydrodissection: injection of fluid to separate the capsule from the cortex. Phacoemulsification: ultrasonic fragmentation and aspiration of the opacified lens through a micro-incision.

IOL insertion: placement of the intraocular lens in the posterior chamber.

OpHLINE 1.4% OVD was used as an adjunct during these phases to maintain the anterior chamber space and protect ocular tissues. After lens implantation, the viscoelastic device were aspirated according to standard surgical practice.

Cataract Surgery by Phacoemulsification with Posterior Chamber Intraocular Lens Implantation (OpHLINE 2%)

Device

Eligible patients underwent cataract removal by phacoemulsification, followed by implantation of a posterior chamber intraocular lens (IOL) in a single eye.

The surgical procedure included the following steps:

Capsulorhexis: creation of a continuous circular opening in the anterior capsule of the lens.

Hydrodissection: injection of fluid to separate the capsule from the cortex. Phacoemulsification: ultrasonic fragmentation and aspiration of the opacified lens through a micro-incision.

IOL insertion: placement of the intraocular lens in the posterior chamber.

OpHLINE 2% OVD was used as an adjunct during these phases to maintain the anterior chamber space and protect ocular tissues. After lens implantation, the viscoelastic device were aspirated according to standard surgical practice.

Cataract Surgery by Phacoemulsification with Posterior Chamber Intraocular Lens Implantation (OpHLINE 3%)

Device

Eligible patients underwent cataract removal by phacoemulsification, followed by implantation of a posterior chamber intraocular lens (IOL) in a single eye.

The surgical procedure included the following steps:

Capsulorhexis: creation of a continuous circular opening in the anterior capsule of the lens.

Hydrodissection: injection of fluid to separate the capsule from the cortex. Phacoemulsification: ultrasonic fragmentation and aspiration of the opacified lens through a micro-incision.

IOL insertion: placement of the intraocular lens in the posterior chamber.

OpHLINE 3% OVD was used as an adjunct during these phases to maintain the anterior chamber space and protect ocular tissues. After lens implantation, the viscoelastic device were aspirated according to standard surgical practice.

Primary outcomes

  1. Ability to maintain anterior chamber space during cataract surgery.

    Time frame: 90 days

    This outcome evaluates whether the OpHLINE OVD can maintain a stable and adequate anterior chamber throughout all critical phases of cataract surgery: capsulorhexis, hydrodissection, phacoemulsification, and intraocular lens (IOL) insertion. Surgeons assessed this parameter using a structured questionnaire, classifying the chamber status into four categories: Complete chamber, Adequate working space, Shallow chamber, and Flat. A positive outcome is defined as achieving either a complete chamber or adequate working space in at least 70% of cases. This measure reflects the core functionality of the OVD in providing surgical safety and facilitating precise maneuvers.

  2. Safety evaluation of OpHLINE during and after surgery

    Time frame: 90 days

    This measure involves systematic monitoring and documentation of any serious adverse events related to the device during the entire study period. SAEs include any event that could result in significant harm or require medical intervention. The target is an incidence rate of ≤1%, confirming that the device does not introduce unexpected risks beyond those inherent to cataract surgery.

Secondary outcomes

  1. Assessment of removal difficulty after IOL implantation

    Time frame: 6 hours

    Surgeons classify removal as Easy, Normal, or Problematic. Adequate removal is defined as Easy or Normal in at least 70% of cases

  2. Percentage of endothelial cell density loss

    Time frame: 90 days

    Endothelial cell density was measured using a non-contact specular microscope at baseline and at 90 days post-surgery. The goal is to determine the protective effect of the OVD on corneal tissue during surgery. A loss of ≤12% is considered optimal, as excessive cell loss can compromise corneal transparency and visual outcomes.

  3. Incidence of IOP ≥30 mmHg during follow-up

    Time frame: 90 days

    IOP was measured at all scheduled visits to monitor postoperative pressure changes. The target is ≤13% incidence at 6 hours post-surgery and ≤6% at subsequent visits. Elevated IOP (>30 mmHg) can lead to optic nerve damage if not controlled, so this measure ensures the device does not contribute to clinically significant pressure spikes.

  4. Frequency of non-serious adverse events during follow-up

    Time frame: 90 days

    This includes any minor complications or events that occur during or after surgery, such as mild inflammation or transient discomfort. The acceptable threshold is ≤30% across the study period, aligning with typical postoperative profiles for cataract surgery.

Sponsors and collaborators

Lead sponsor

i+Med S.Coop.

Industry

Collaborators

  • Hospital Universitario Araba
  • Hospital Universitario Basurto

Registry information

Official study title

Post-Market Study for the Evaluation of the Efficacy and Safety of the OpHLINE Ophthalmic Viscosurgical Device (OVD) in Cataract Surgery

Important dates

Study start
2021
Primary completion
2022
Study completion
2022
First posted
Jan 15, 2026
Registry last updated
Feb 11, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.